Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease
Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products ...
Le Lézard1d
Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson's ...
Last-minute gift ideas for 2024
Finding the perfect gift can be a challenge, especially as time runs out. That’s why we’ve rounded up thoughtful and unique ...
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...
manilatimes19h
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Agreement Reached on Primary Endpoint and Phase 3 Trial Design. Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering. FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE ...
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies
Improvements Across Measures of Behavior, Function, Cognition and Movement -- Expediting Plans to Advance CT1812 into Late-Stage Trials -- Full ...
Business Wire3d
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Pha ...
Cognition Therapeutics, Inc.: Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies
Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body ...
The Globe and Mail5d
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition
Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.
PipelineReview.com1d
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
DUBLIN, Ireland I 19, 2024 I Prothena Corporation plc (NASDAQ:PRTA), today announced results from the Phase IIb PADOVA study conducted by partner ...
themarijuanaherald3d
MindMed Launches Phase 3 Trials for LSD-Based Treatment to Tackle Anxiety Disorders, Announces First Patient Dosed
Mind Medicine Inc., a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health ...